Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem(Universitair Ziekenhuis Leuven), Malcolm J. Moore(University Health Network), Jean‐Luc Van Laethem(Deventer Ziekenhuis), Jaafar Bennouna(Sorbonne Université), Sharlene Gill(Deventer Ziekenhuis), Aijing Shang(Deventer Ziekenhuis), Jan Cosaert(AstraZeneca (United Kingdom)), Werner Scheithauer(Comprehensive Cancer Center Vienna), Chris Verslype(KU Leuven), Yves Humblet(Deventer Ziekenhuis), Walter L. Vervenne(Deventer Ziekenhuis)
Cited by 643
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k